GPCR and EGFR are two pivotal families of drug targets, given that GPCR-induced transactivation of EGFR has been linked to cancer development (Köse, 2017), through the activation of MAPK signaling, stimulation of cell migration, and regulation of cell-cycle progression. The gene discussed is LPAR3; the disease is cancer.